By Liz Essley Whyte A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic...
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.
Patients last year petitioned the FDA to consider the treatment, called NurOwn, in a public hearing. The agency said the company submitted"scientifically incomplete" and"grossly deficient" data.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Soleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study ResultsThe biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
続きを読む »
Amgen discloses more than $400 million stake in recent IPO Neumora TherapeuticsAn Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.
続きを読む »
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
続きを読む »
San Diego biotech will pay $200K after allegations of misleading claimsBiora Therapeutics made misleading claims regarding the costs of genetic testing services
続きを読む »
Average teen gets more than 230 notifications on their cell phone each day, study findsA new study is shining a light on the amount of time teenagers are spending on their cell phones and social media every day.
続きを読む »